ReviewMovement disorders clinical practice2014
Treatment Options in Degenerative Cerebellar Ataxia: A Systematic Review.
Review in Movement disorders clinical practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Pharmacological and non-pharmacological management of spinocerebellar ataxia: A systematic review.Journal of neurology · 2022Pooled it
- Cerebellar Degeneration in Epilepsy: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Efficacy of Cerebellar Transcranial Direct Current Stimulation in Degenerative Ataxia. A Sham-Controlled Clinical and Quantitative Analysis.Cerebellum (London, England) · 2026Trial
- Tai Chi for Dynamic Balance Training Among Individuals with Cerebellar Ataxia: An Assessor-Blinded Randomized-Controlled Trial.Journal of integrative and complementary medicine · 2022Trial
- Spinocerebellar Ataxia Type 12: Spectrums of Movement Disorders and Clinical Features.Neuro-degenerative diseases · 2026Review
- Changes in Gait After Training for Individuals With Cerebellar Ataxia.Archives of rehabilitation research and clinical translation · 2025Article
- An Imitation-Based Treatment for Ataxic Dysarthria: A Retrospective Multiple Single-Case Study.Biomedicines · 2025Article
- Alcohol and alcoholism associated neurological disorders: Current updates in a global perspective and recent recommendations.World journal of experimental medicine · 2025Review
- Scorpionism in Pará, Brazil: Clinical assessment of neuromuscular manifestations.Revista da Sociedade Brasileira de Medicina Tropical · 2025Observational
- Protein sequence analysis in the context of drug repurposing.BMC medical informatics and decision making · 2024Article
- Oxidative stress and ion channels in neurodegenerative diseases.Frontiers in physiology · 2024Review
- Clinical value of vestibulo-ocular reflex in the differentiation of spinocerebellar ataxias.Scientific reports · 2023Article
- Article
- Mesenchymal Stem Cell Transplantation Ameliorates Ara-C-Induced Motor Deficits in a Mouse Model of Cerebellar Ataxia.Journal of clinical medicine · 2023Article
- Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Hypertrophic olivary degeneration and palatal myoclonus from aJournal of neurosurgery. Case lessons · 2022Article
- Upper Body Physical Rehabilitation for Children with Ataxia through IMU-Based Exergame.Journal of clinical medicine · 2022Article
- Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo-controlled trials.Journal of neurology · 2022Review
- Efficient Neuroprotective Rescue of Sacsin-Related Disease Phenotypes in Zebrafish.International journal of molecular sciences · 2021Article
- Spinocerebellar ataxia clinical trials: opportunities and challenges.Annals of clinical and translational neurology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The etiology of cerebellar ataxia (CA) is heterogeneous and includes easily identified and often reversible causes (i.e., drug toxicity and vitamin B12 deficiency) as well as irreversible degenerative conditions. It is the latter that poses a significant therapeutic challenge for practitioners treating this population of patients. To date, there are no U.S. Food and Drug Administration-approved medications for the treatment of CA. The literature, consisting mostly of case reports, case series, and small clinical trials, is sparse and scattered. These studies are difficult to translate clinically because they often describe diverse study populations with various identified and unidentified genetic etiologies. In addition, the reported treatment duration is often brief, and it is uncertain whether any of these options provide substantially lasting benefits. In this article, we review published reports and studies to aid the practitioner counseling patients with degenerative ataxias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.